DNA methylation may mediate psychotropic drug-induced metabolic side effects: results from a 1-month observational study
| Autor: | C. Dubath, E. Porcu, A. Delacrétaz, C. Grosu, N. Laaboub, M. Piras, A. Von Gunten, P. Conus, K. Von Plessen, Z. Kutalik, C. Eap |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | European Psychiatry, Vol 65, Pp S98-S99 (2022) |
| Druh dokumentu: | article |
| ISSN: | 0924-9338 1778-3585 |
| DOI: | 10.1192/j.eurpsy.2022.285 |
| Popis: | Introduction Metabolic side effects of psychotropic medications are a major drawback to patients’ effective treatment. Among the mechanisms underlying their development, DNA methylation may be involved. Objectives The aim of this study was to estimate DNA methylation changes occurring secondary to psychotropic treatment and evaluate associations between 1-month metabolic changes and baseline DNA methylation or 1-month DNA methylation changes, using an epigenome-wide approach. Methods Seventy-nine psychiatric patients recruited as part of PsyMetab study, who started a treatment with either an antipsychotic, a mood stabilizer or mirtazapine were selected. Epigenome-wide DNA methylation was measured using the Illumina Methylation EPIC BeadChip at baseline and after one month of treatment. Results A global methylation increase was observed after 1 month of treatment, which was more pronounced in patients whose weight remained stable (i.e., |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|